指南与共识呼吸道感染

儿童社区获得性肺炎氨苄西林与头孢曲松给药方案的蒙特卡洛及生理药代动力学模拟评价

Dosing Recommendations for Ampicillin and Ceftriaxone in the Treatment of Pediatric Community-Acquired Pneumonia Using Monte Carlo- and Physiologic-Based Pharmacokinetic Simulations
RSS 订阅 · 指南共识 · 肺炎 · 2025-06-19

该研究基于21株儿童CAP肺炎链球菌药敏数据,用蒙特卡洛模拟(N=10000)和生理药代动力学模型(AMP N=4000、CRO N=3000)评估6个年龄虚拟患儿现行推荐剂量的达标概率。结果显示现行AMP与CRO方案在血清和肺上皮衬液均达>99% PTA(30%–50% fT>MIC),提示标准剂量对>98%患儿可获得临床与微生物学成功。

要点

  • 现行标准剂量AMP与CRO在血清及肺ELF的PTA均>99%,支持经验性用药。
  • 按CLSI/FDA折点21株肺炎链球菌对AMP和CRO均100%敏感。
  • 按EUCAST/EMA折点敏感率AMP为85.7%、CRO为90.5%。

核心结论

  • 在肺炎球菌结合疫苗时代,AMP与CRO标准剂量可为>98%的儿童CAP患儿提供合适的血清和肺ELF暴露,支持临床与微生物学成功。
  • 若肺炎球菌对β-内酰胺类耐药性增加,达到目标结局所需剂量可能改变。

研究设计与样本

  • 采用非线性混合效应模型v7.3进行蒙特卡洛模拟,AMP与CRO各N=10000。
  • 用PK-Sim v9.0建立PBPK模型,AMP N=4000、CRO N=3000。
  • 虚拟患者为3月龄、1、2、5、10、15岁共6个年龄段。
  • 药敏数据来自21株儿童CAP分离的肺炎链球菌。

主要发现

  • 按CLSI/FDA折点,21株(100%)对AMP和CRO均敏感。
  • 按EUCAST/EMA折点,18株(85.7%)对AMP敏感、19株(90.5%)对CRO敏感。
  • MCS与PBPK模拟显示AMP和CRO方案在血清与ELF的PTA均>99%(30%–50% fT>MIC)。

关键数值与推荐

  • CLSI/FDA折点:CRO敏感/中介/耐药为≤1、2、≥4 mg/L;AMP(由青霉素外推)为≤2、4、≥8 mg/L。
  • EUCAST/EMA折点:CRO敏感与不敏感为0.5与2 mg/L;AMP为0.5与1 mg/L。
  • PK/PD目标为游离药物浓度超过MIC的时间占给药间期的30%–50%(%fT>MIC)。

临床怎么用

  • 儿童CAP经验性治疗可沿用现行AMP与CRO标准剂量,血清与肺内暴露预期达标。
  • 对未接种疫苗或复杂性CAP选用CRO时,现有剂量在模拟中显示充分覆盖。
  • 应持续监测本地肺炎球菌β-内酰胺耐药趋势,耐药上升时需重新评估剂量。

局限性

  • 模拟仅基于21株肺炎球菌药敏数据,样本量有限。
  • 结论依赖虚拟患者与模型假设,尚需临床结局数据验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

J Pediatr Pharmacol Ther. 2025 Jun;30(3):352-361. doi: 10.5863/JPPT-24-00069. Epub 2025 Jun 9. ABSTRACT OBJECTIVE: Since 2011, Ampicillin (AMP) has been recommended as the parenteral antibiotic of choice for pediatric community-acquired pneumonia (CAP), but ceftriaxone (CRO) is recommended for unvaccinated children and those with complicated CAP. Using penicillin and CRO susceptibility data for pneumococcus, we evaluated the adequacy of currently recommended doses of AMP and CRO. METHODS: With nonlinear mixed-effects modeling v7.3, Monte Carlo simulations (MCS, N = 10,000) for AMP and CRO were conducted for 6 virtual patients aged 3 months, 1, 2, 5, 10, and 15 years. PK-Sim v9.0 was used to develop physiologic-based pharmacokinetic (PBPK) models for AMP (N = 4000) and CRO (N = 3000). The probability of target attainment (PTA) was determined for both serum and lung (epithelial lining fluid [ELF]) exposure to achieve free drug concentrations above the minimum inhibitory concentration (% f T>MIC) for pneumococci at 30% to 50% of the dosing interval. RESULTS: We performed simulations based on susceptibility data from 21 pneumococci isolated from children with CAP and found all 21 (100%) to be susceptible to AMP and CRO using Clinical & Laboratory Standard Institute/US Food and Drug Administration breakpoints, where susceptible, intermediate, and resistant strains of Streptococcus pneumoniae were ≤1, 2, and ≥4 mg/L for CRO and ≤2, 4, and ≥8 mg/L for AMP (extrapolated from penicillin), respectively (where intermediate and resistant were considered nonsusceptible); and 18 (85.7%) were susceptible to AMP, and 19 (90.5%) to CRO using the European Committee on Antimicrobial Susceptibility Testing/European Medicines Agency breakpoints, where susceptible and nonsusceptible strains were as follows: 0.5 and 2 mg/L for CRO and 0.5 and 1 mg/L for AMP. Both the serum and ELF, antibiotic regimens achieved >99% PTA at 30% to 50% f T>MIC using MCS and PBPK. CONCLUSION: In the pneumococcal conjugate era, standard doses of AMP and CRO appear to provide the appropriate serum and ELF exposure for clinical and microbiologic success for >98% of children with pediatric CAP. The required dose to achieve the desired outcomes may change if beta-lactam resistance in pneumococcus increases. PMID: 40534929 | PMC: PMC12172679 | DOI: 10.5863/JPPT-24-00069

来源:指南共识 · 肺炎,查看原文。版权归原作者所有。

引用

  1. 指南共识 · 肺炎:Dosing Recommendations for Ampicillin and Ceftriaxone in the Treatment of Pediatric Community-Acquired Pneumonia Using Monte Carlo- and Physiologic-Based Pharmacokinetic Simulations

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。